Dr. Boyle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12902 Usf Magnolia Dr
# Moffitt
Tampa, FL 33612Phone+1 813-745-4673
Summary
- Dr. Theresa Boyle is a pathologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from Howard University College of Medicine and has been in practice 15 years. She specializes in molecular genetics, anatomic pathology, and clinical pathology.
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Molecular Genetic Pathology, 2011 - 2012
- University of ColoradoResidency, Pathology-Anatomic and Clinical, 2007 - 2011
- University of Colorado at DenverPhD, Human Medical Genetics, 2003 - 2007
- Georgetown University HospitalInternship, Transitional Year, 2002 - 2003
- Howard University College of MedicineClass of 2002
Certifications & Licensure
- FL State Medical License 2015 - 2026
- CO State Medical License 2003 - 2025
- CA State Medical License Active through 2013
- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Pathology - Molecular Genetic
Publications & Presentations
PubMed
- 24 citationsA phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.Jhanelle E. Gray, Alberto Chiappori, Charles Williams, Tawee Tanvetyanon, Eric B. Haura
Cancer Immunology, Immunotherapy. 2018-09-12 - 146 citationsClinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.Anna F. Farago, Martin S. Taylor, Robert C. Doebele, Viola W. Zhu, Shivaani Kummar
JCO Precision Oncology. 2017-05-30 - 256 citationsLandscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.Xiuning Le, Sonam Puri, Marcelo V. Negrao, Monique B. Nilsson, Jacqulyne P. Robichaux
Clinical Cancer Research. 2018-12-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: